Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Polymet Mining Corp T.POM

PolyMet Mining Corp. is a mine development company. The Company is engaged in mining copper, nickel and precious metals from the NorthMet ore body. The Company owns the NorthMet Project and Mesaba Project, which is a copper, nickel, cobalt and platinum group metal (PGM) deposits. The NorthMet deposit is located in the Partridge River Intrusion of the Duluth Complex, a geological formation near the eastern end of the Mesabi Iron Range, which is an undeveloped accumulation of copper, nickel and platinum group metals. The Mesaba Project is located in St. Louis County, Minnesota. Its NorthMet is a disseminated sulfide deposit in heterogeneous troctolitic rocks associated with Mid-continent Rift, and is rich with copper, nickel, cobalt, platinum, palladium, gold and silver. The majority of the metals are concentrated in, or associated with, four sulfide minerals: chalcopyrite, cubanite, pentlandite and pyrrhotite.


TSX:POM - Post by User

Post by SallySaon Jun 03, 2022 5:18am
151 Views
Post# 34728763

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance




FSD Pharma ready to proceed with Phase 2 clinical trial of FSD-201 as soon as it gets clearance
 
FSD Pharma Inc CEO Anthony Durkacz told Proactive that the company is ready to proceed with the planned Phase 2 clinical trial of its FSD-201 drug candidate as soon as it gets the go-ahead from the US Food and Drug Administration and Health Canada. That's after submitting Investigational New Drug (IND) applications to the two bodies this week. Armed with cash of about $50 million following the $16.4 million disposal of its former cannabis production facility in Ontario, Durkacz said FSD is also moving full-steam ahead on its two other drug candidates and may look for other opportunities. A special dividend may also be on the cards, he added.


<< Previous
Bullboard Posts
Next >>